KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Consolidated Net Income: 2017-2025

Historic Consolidated Net Income for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$200.0 million.

  • Moderna's Consolidated Net Income fell 1638.46% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 40.11%. This contributed to the annual value of -$3.6 billion for FY2024, which is 24.46% up from last year.
  • Per Moderna's latest filing, its Consolidated Net Income stood at -$200.0 million for Q3 2025, which was up 75.76% from -$825.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's Consolidated Net Income ranged from a high of $4.9 billion in Q4 2021 and a low of -$3.6 billion during Q3 2023.
  • For the 3-year period, Moderna's Consolidated Net Income averaged around -$933.7 million, with its median value being -$971.0 million (2025).
  • As far as peak fluctuations go, Moderna's Consolidated Net Income surged by 2,476.07% in 2021, and later crashed by 1,638.46% in 2025.
  • Moderna's Consolidated Net Income (Quarterly) stood at $4.9 billion in 2021, then plummeted by 69.91% to $1.5 billion in 2022, then crashed by 85.19% to $217.0 million in 2023, then slumped by 616.13% to -$1.1 billion in 2024, then slumped by 1,638.46% to -$200.0 million in 2025.
  • Its Consolidated Net Income stands at -$200.0 million for Q3 2025, versus -$825.0 million for Q2 2025 and -$971.0 million for Q1 2025.